Tafinlar
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
GL We undertook the COMBI-AD study (Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma) because the COMBI-v…
The FDA has granted priority review to the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the adjuvant…
KF Like other combinations of BRAF and MEK inhibitors, encorafenib/binimetinib has been dem on strated to be superior to…
DJ The US Food and Drug Administration has approved 2 MEK inhibitors for use in advanced BRAF V600mutant melanoma: trametinib…
Despite the continuously increasing incidence of melanoma, over decades the therapy has barely changed. However, since 2011 the…
MD The US Food Administration (FDA) has approved several molecularly targeted agents for use in patients with metastatic melanoma…
HT To give some background, the treatment of metastatic melanoma was revolutionized by the development of targeted therapy using…
Webster and Mentzer discuss the market landscape for malignant melanoma — a cancer for which treatment options have broadened…